The first-line use of pembrolizumab, an anti-PD1 antibody, has longer progression-free and overall survival than platinum-based chemotherapy in advanced non-small-cell lung cancer (NSCLC) with PDL1 expression at least 50% of tumor cells [2]. This evidence concerns the gene CD274 and neoplasm.